DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for alopecia universalis congenita — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAlopecia universalis congenita maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for alopecia universalis congenita is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In a 2013 study of pulse methylprednisolone therapy for extensive alopecia areata, 15 patients received 500 mg intravenously for three consecutive days each month for three months and were followed for three months. Among eight patients with alopecia universalis, one had significant regrowth (more than 50%) and one had minimal regrowth (less than 50%); the remaining six had no regrowth. In three patients with alopecia totalis, none had any regrowth. The authors concluded that results in alopecia totalis or universalis were unsatisfactory.
A 2022 review notes that for patients with severe alopecia areata, progression to alopecia totalis or alopecia universalis occurs in about a third of cases, and recovery from that extreme extent of disease is rare. It states that for many patients with severe disease, medical treatments do not work.
A 1963 case report describes a patient with alopecia universalis of 54 years’ duration. Rapid hair regrowth occurred after starting prednisolone therapy, but hair did not persist after the drug was withdrawn. The daily steroid dose needed to produce regrowth was less than the average daily endogenous steroid secretion of normal individuals.
What is still missing are prospective trials large enough to detect meaningful response rates in alopecia universalis congenita specifically, and any evidence that regrowth, if achieved, can be maintained without continuous treatment. No study has identified which patients, if any, are likely to respond, and no trial has addressed the cost or long-term safety of the steroid doses required.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Dermatological Treatment · 2013 · 24 citations
Pulse methylprednisolone therapy for the treatment of extensive alopecia areata
AbstractBACKGROUND: Since the mainstay of pathogenesis depends on autoimmune process, systemic steroids are widely used in the treatment of alopecia with various side effects. To avoid side effects of long-term steroid treatment, pulse methylprednisolone therapy appears to be a safe treatment option. OBJECTIVE: The aim was to determine the effect of pulse methylprednisolone therapy for the treatment of adult alopecia areata. METHODS: Demographical features of all patients were recorded before the treatment. Patients received methylprednisolone 500 mg intravenously for 3 consecutive days every month for 3 months. Patients were followed up for 3 months. Treatment responses were defined by complete regrowth (100%), significant regrowth (>50%) and minimal regrowth (<50%). RESULTS: Totally 15 patients were enrolled in this study. At the end of the study, two patients had significant regrowth and one patient had minimal regrowth in multifocal alopecia areata (n = 4); one patient had significant regrowth and one patient had minimal regrowth in alopecia universalis (n = 8); three patients had no regrowth in alopecia totalis (n = 3). CONCLUSIONS: The study suggests that pulse methylprednisolone therapy might be a therapeutic option for severe multifocal alopecia areata. However, in alopecia totalis or universalis, treatment results are unsatisfactory.
New England Journal of Medicine · 2022 · 16 citations
Baricitinib in Alopecia Areata
AbstractFor many people, alopecia areata is a transient problem, in which small patches of hair loss recover spontaneously within a few months. But for others, the reality is rather different. An Italian study showed that one third of patients with scalp hair loss of 25 to 50% still had active patchy disease at long-term follow-up, with a further third having progression to alopecia totalis or alopecia universalis, terms that vividly capture the extreme extent of disease and from which recovery is rare.1 For many patients with severe disease, medical treatments do not work, and they face difficulty in coping with . . .
AbstractThe literature concerning the etiology and treatment of alopecia is reviewed. A case is presented of alopecia universalis of 54 years<sup>'</sup>duration. The only significant systemic abnormality found on a thorough pretreatment evaluation of the patient was evidence of mildly decreased adrenal function. Skin biopsies before treament revealed no pathology except lack of a hair shaft. A rapid hair regrowth occurred after the institution of prednisolone therapy; the hair did not persist after the drug was withdrawn. The daily dosage of steroid necessary to produce hair regrowth was found to be less than the average daily endogenous steroid secretion of normals.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2008 · 0 citations
Faculty Opinions recommendation of Successful treatment of alopecia universalis with alefacept: a case report and review of the literature.
AbstractAlopecia universalis often responds poorly to standard therapies. We report how a novel treatment option, alefacept, was successfully used in the management of a 21-year-old woman with alopecia universalis. The patient responded with complete regrowth of scalp and body hair after a single 12-week treatment course of alefacept. In addition, a review of the literature was performed pertaining to the use of biologic agents in the treatment of alopecia areata/universalis to determine which agents have a potential role in the treatment of this often refractory disease. PMID: 18543595
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
